{"id":970886,"date":"2026-06-04T16:34:53","date_gmt":"2026-06-04T20:34:53","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-announces-presentation-of-updated-data-from-investigator-initiated-islet-transplant-trial-of-tegoprubart-in-patients-with-type-1-diabetes-at-american-diabetes-association-ada-2026-scientific\/"},"modified":"2026-06-04T16:34:53","modified_gmt":"2026-06-04T20:34:53","slug":"eledon-announces-presentation-of-updated-data-from-investigator-initiated-islet-transplant-trial-of-tegoprubart-in-patients-with-type-1-diabetes-at-american-diabetes-association-ada-2026-scientific","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-announces-presentation-of-updated-data-from-investigator-initiated-islet-transplant-trial-of-tegoprubart-in-patients-with-type-1-diabetes-at-american-diabetes-association-ada-2026-scientific\/","title":{"rendered":"Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions"},"content":{"rendered":"
\n

IRVINE, Calif., June 04, 2026 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (\u201cEledon\u201d) (Nasdaq: ELDN) today announced that updated results from an investigator-initiated trial being conducted at the University of Chicago Medicine Transplant Institute will be presented by Piotr Witkowski, M.D., Ph.D., Director of the Pancreas and Islet Transplant Program at UChicago Medicine, at the American Diabetes Association 86th Scientific Sessions, taking place June 5-9, 2026, in New Orleans, Louisiana.<\/p>\n

Details of the oral presentation are as follows:<\/p>\n

\n Presentation Title:<\/strong> Anti-CD40L to Induce Graft Survival and Function in Islet Allotransplantation
Session:<\/strong> Immune Modulatory Strategies for Next-Generation Cell Therapies
Date:<\/strong> Sunday, June 7, 2026
Time:<\/strong> 2:30 p.m. \u2013 3:00 p.m. CT
Room: <\/strong>343 (Level 3)<\/p>\n

\n About\u00a0Eledon Pharmaceuticals\u00a0and tegoprubart<\/strong>\n <\/p>\n

Eledon Pharmaceuticals, Inc.\u00a0is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company\u2019s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, liver transplantation and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in\u00a0Irvine, California. For more information, please visit the Company\u2019s website at\u00a0www.eledon.com<\/a>.<\/p>\n

Follow\u00a0Eledon Pharmaceuticals\u00a0on social media:\u00a0LinkedIn<\/a>;\u00a0Twitter<\/a><\/p>\n

\n Investor Contact:
<\/strong>Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com<\/a><\/p>\n

\n Media Contact:
<\/strong>Jenna Urban
CG Life
(212) 253 8881
jurban@cglife.com<\/a><\/p>\n

Source:\u00a0Eledon Pharmaceuticals<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

IRVINE, Calif., June 04, 2026 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (\u201cEledon\u201d) (Nasdaq: ELDN) today announced that updated results from an investigator-initiated trial being conducted at the University of Chicago Medicine Transplant Institute will be presented by Piotr Witkowski, M.D., Ph.D., Director of the Pancreas and Islet Transplant Program at UChicago Medicine, at the American Diabetes Association 86th Scientific Sessions, taking place June 5-9, 2026, in New Orleans, Louisiana. Details of the oral presentation are as follows: Presentation Title: Anti-CD40L to Induce Graft Survival and Function in Islet AllotransplantationSession: Immune Modulatory Strategies for Next-Generation Cell TherapiesDate: Sunday, June 7, 2026Time: 2:30 p.m. \u2013 3:00 p.m. CTRoom: 343 (Level 3) About\u00a0Eledon Pharmaceuticals\u00a0and tegoprubart Eledon Pharmaceuticals, Inc.\u00a0is a clinical stage biotechnology company … <\/p>\n

Continue reading “Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-970886","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-announces-presentation-of-updated-data-from-investigator-initiated-islet-transplant-trial-of-tegoprubart-in-patients-with-type-1-diabetes-at-american-diabetes-association-ada-2026-scientific\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"IRVINE, Calif., June 04, 2026 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (\u201cEledon\u201d) (Nasdaq: ELDN) today announced that updated results from an investigator-initiated trial being conducted at the University of Chicago Medicine Transplant Institute will be presented by Piotr Witkowski, M.D., Ph.D., Director of the Pancreas and Islet Transplant Program at UChicago Medicine, at the American Diabetes Association 86th Scientific Sessions, taking place June 5-9, 2026, in New Orleans, Louisiana. Details of the oral presentation are as follows: Presentation Title: Anti-CD40L to Induce Graft Survival and Function in Islet AllotransplantationSession: Immune Modulatory Strategies for Next-Generation Cell TherapiesDate: Sunday, June 7, 2026Time: 2:30 p.m. \u2013 3:00 p.m. CTRoom: 343 (Level 3) About\u00a0Eledon Pharmaceuticals\u00a0and tegoprubart Eledon Pharmaceuticals, Inc.\u00a0is a clinical stage biotechnology company … Continue reading "Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-announces-presentation-of-updated-data-from-investigator-initiated-islet-transplant-trial-of-tegoprubart-in-patients-with-type-1-diabetes-at-american-diabetes-association-ada-2026-scientific\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-04T20:34:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMjE4NCM3NjM3NDUzIzIwMDY1NTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-announces-presentation-of-updated-data-from-investigator-initiated-islet-transplant-trial-of-tegoprubart-in-patients-with-type-1-diabetes-at-american-diabetes-association-ada-2026-scientific\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-announces-presentation-of-updated-data-from-investigator-initiated-islet-transplant-trial-of-tegoprubart-in-patients-with-type-1-diabetes-at-american-diabetes-association-ada-2026-scientific\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions\",\"datePublished\":\"2026-06-04T20:34:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-announces-presentation-of-updated-data-from-investigator-initiated-islet-transplant-trial-of-tegoprubart-in-patients-with-type-1-diabetes-at-american-diabetes-association-ada-2026-scientific\\\/\"},\"wordCount\":297,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-announces-presentation-of-updated-data-from-investigator-initiated-islet-transplant-trial-of-tegoprubart-in-patients-with-type-1-diabetes-at-american-diabetes-association-ada-2026-scientific\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTczMjE4NCM3NjM3NDUzIzIwMDY1NTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-announces-presentation-of-updated-data-from-investigator-initiated-islet-transplant-trial-of-tegoprubart-in-patients-with-type-1-diabetes-at-american-diabetes-association-ada-2026-scientific\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-announces-presentation-of-updated-data-from-investigator-initiated-islet-transplant-trial-of-tegoprubart-in-patients-with-type-1-diabetes-at-american-diabetes-association-ada-2026-scientific\\\/\",\"name\":\"Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-announces-presentation-of-updated-data-from-investigator-initiated-islet-transplant-trial-of-tegoprubart-in-patients-with-type-1-diabetes-at-american-diabetes-association-ada-2026-scientific\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-announces-presentation-of-updated-data-from-investigator-initiated-islet-transplant-trial-of-tegoprubart-in-patients-with-type-1-diabetes-at-american-diabetes-association-ada-2026-scientific\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTczMjE4NCM3NjM3NDUzIzIwMDY1NTA=\",\"datePublished\":\"2026-06-04T20:34:53+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-announces-presentation-of-updated-data-from-investigator-initiated-islet-transplant-trial-of-tegoprubart-in-patients-with-type-1-diabetes-at-american-diabetes-association-ada-2026-scientific\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-announces-presentation-of-updated-data-from-investigator-initiated-islet-transplant-trial-of-tegoprubart-in-patients-with-type-1-diabetes-at-american-diabetes-association-ada-2026-scientific\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-announces-presentation-of-updated-data-from-investigator-initiated-islet-transplant-trial-of-tegoprubart-in-patients-with-type-1-diabetes-at-american-diabetes-association-ada-2026-scientific\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTczMjE4NCM3NjM3NDUzIzIwMDY1NTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTczMjE4NCM3NjM3NDUzIzIwMDY1NTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-announces-presentation-of-updated-data-from-investigator-initiated-islet-transplant-trial-of-tegoprubart-in-patients-with-type-1-diabetes-at-american-diabetes-association-ada-2026-scientific\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-announces-presentation-of-updated-data-from-investigator-initiated-islet-transplant-trial-of-tegoprubart-in-patients-with-type-1-diabetes-at-american-diabetes-association-ada-2026-scientific\/","og_locale":"en_US","og_type":"article","og_title":"Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions - Market Newsdesk","og_description":"IRVINE, Calif., June 04, 2026 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (\u201cEledon\u201d) (Nasdaq: ELDN) today announced that updated results from an investigator-initiated trial being conducted at the University of Chicago Medicine Transplant Institute will be presented by Piotr Witkowski, M.D., Ph.D., Director of the Pancreas and Islet Transplant Program at UChicago Medicine, at the American Diabetes Association 86th Scientific Sessions, taking place June 5-9, 2026, in New Orleans, Louisiana. Details of the oral presentation are as follows: Presentation Title: Anti-CD40L to Induce Graft Survival and Function in Islet AllotransplantationSession: Immune Modulatory Strategies for Next-Generation Cell TherapiesDate: Sunday, June 7, 2026Time: 2:30 p.m. \u2013 3:00 p.m. CTRoom: 343 (Level 3) About\u00a0Eledon Pharmaceuticals\u00a0and tegoprubart Eledon Pharmaceuticals, Inc.\u00a0is a clinical stage biotechnology company … Continue reading \"Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-announces-presentation-of-updated-data-from-investigator-initiated-islet-transplant-trial-of-tegoprubart-in-patients-with-type-1-diabetes-at-american-diabetes-association-ada-2026-scientific\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-04T20:34:53+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMjE4NCM3NjM3NDUzIzIwMDY1NTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-announces-presentation-of-updated-data-from-investigator-initiated-islet-transplant-trial-of-tegoprubart-in-patients-with-type-1-diabetes-at-american-diabetes-association-ada-2026-scientific\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-announces-presentation-of-updated-data-from-investigator-initiated-islet-transplant-trial-of-tegoprubart-in-patients-with-type-1-diabetes-at-american-diabetes-association-ada-2026-scientific\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions","datePublished":"2026-06-04T20:34:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-announces-presentation-of-updated-data-from-investigator-initiated-islet-transplant-trial-of-tegoprubart-in-patients-with-type-1-diabetes-at-american-diabetes-association-ada-2026-scientific\/"},"wordCount":297,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-announces-presentation-of-updated-data-from-investigator-initiated-islet-transplant-trial-of-tegoprubart-in-patients-with-type-1-diabetes-at-american-diabetes-association-ada-2026-scientific\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMjE4NCM3NjM3NDUzIzIwMDY1NTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-announces-presentation-of-updated-data-from-investigator-initiated-islet-transplant-trial-of-tegoprubart-in-patients-with-type-1-diabetes-at-american-diabetes-association-ada-2026-scientific\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-announces-presentation-of-updated-data-from-investigator-initiated-islet-transplant-trial-of-tegoprubart-in-patients-with-type-1-diabetes-at-american-diabetes-association-ada-2026-scientific\/","name":"Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-announces-presentation-of-updated-data-from-investigator-initiated-islet-transplant-trial-of-tegoprubart-in-patients-with-type-1-diabetes-at-american-diabetes-association-ada-2026-scientific\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-announces-presentation-of-updated-data-from-investigator-initiated-islet-transplant-trial-of-tegoprubart-in-patients-with-type-1-diabetes-at-american-diabetes-association-ada-2026-scientific\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMjE4NCM3NjM3NDUzIzIwMDY1NTA=","datePublished":"2026-06-04T20:34:53+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-announces-presentation-of-updated-data-from-investigator-initiated-islet-transplant-trial-of-tegoprubart-in-patients-with-type-1-diabetes-at-american-diabetes-association-ada-2026-scientific\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/eledon-announces-presentation-of-updated-data-from-investigator-initiated-islet-transplant-trial-of-tegoprubart-in-patients-with-type-1-diabetes-at-american-diabetes-association-ada-2026-scientific\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-announces-presentation-of-updated-data-from-investigator-initiated-islet-transplant-trial-of-tegoprubart-in-patients-with-type-1-diabetes-at-american-diabetes-association-ada-2026-scientific\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMjE4NCM3NjM3NDUzIzIwMDY1NTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMjE4NCM3NjM3NDUzIzIwMDY1NTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-announces-presentation-of-updated-data-from-investigator-initiated-islet-transplant-trial-of-tegoprubart-in-patients-with-type-1-diabetes-at-american-diabetes-association-ada-2026-scientific\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/970886","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=970886"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/970886\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=970886"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=970886"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=970886"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}